National Center for Advancing Translational Sciences to Grant Exclusive Patent License for Cancer Treatment

Summary

The National Center for Advancing Translational Sciences, part of the National Institutes of Health, is considering granting an exclusive patent license to Platform Pharmaceuticals for its Mutant IDH1 inhibitors, which could be used to treat cancer.